2017 Taiwan lipid guidelines for high risk patients

Keyphrases

• Taiwan 100%
• Low-density Lipoprotein Cholesterol (LDL-C) 100%
• Clinical High Risk 100%
• Lipid Guidelines 100%
• Statins 66%
• Homozygous Familial Hypercholesterolemia (HoFH) 66%
• Atherosclerotic Cardiovascular Disease (ASCVD) 33%
• Coronary Artery Disease 33%
• Chronic Kidney Disease 33%
• Ezetimibe 33%
• Lipid-lowering Drugs 33%
• Lipid Control 33%
• Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors 33%
• Clinical Practice Guidelines 16%
• Cardiovascular Risk 16%
• Peripheral Arterial Disease 16%
• Clinical Setting 16%
• Healthcare Professionals 16%
• Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) 16%
• Apolipoprotein B (Apo B) 16%
• Cholesterol Absorption Inhibitor 16%
• Clinical Outcomes 16%
• Lipids 16%
• Physical Limitations 16%
• Type 1 Diabetes Mellitus (T1DM) 16%
• Lifestyle Modification 16%
• Common Cause 16%
• Combination Therapy 16%
• Non-high-density Lipoprotein Cholesterol (non-HDL-C) 16%
• Predictive Factors 16%
• Weight Reduction 16%
• Chronic Kidney Disease Stage 16%
• Control Rate 16%
• Statin Therapy 16%
• Acute Coronary Syndrome 16%
• Family History 16%
• Triglyceride Level 16%
• First-line Therapy 16%
• Ischemic Stroke 16%
• Patients with Diabetes Mellitus 16%
• Chronic Kidney Disease Patients 16%
• Lifestyle Habits 16%
• Clinical History 16%
• HMG-CoA Reductase Inhibitors 16%
• Major Purpose 16%
• Glomerular Filtration Rate 16%
• Adjunctive Therapy 16%
• Physical Findings 16%
• Stable Coronary Artery Disease 16%
• Chronic Dialysis 16%
• Lipid-lowering Agents 16%
• Lipid-lowering Therapy 16%
• Prescription Rate 16%
• Alcohol Intake 16%
• LDL Receptor 16%
• Regular Physical Exercise 16%
• Dietary Habits Changes 16%
• Lomitapide 16%
• Allreduce 16%
• Corneal Arcus 16%
• Premature Coronary Artery Disease 16%
• Fibric Acid Derivatives 16%
• Nicotinic Acid 16%
• Xanthoma 16%
• Mipomersen 16%
• Long-chain n-3 Polyunsaturated Fatty Acids 16%
• Niacin 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Low Density Lipoprotein Cholesterol 100%
• Statin (Protein) 80%
• Familial Hypercholesterolemia 80%
• Coronary Artery Disease 80%
• Hyperlipidemia 80%
• Chronic Kidney Failure 80%
• Proprotein Convertase 9 60%
• Antilipemic Agent 60%
• Coronary Artery Atherosclerosis 40%
• Diabetes Mellitus 40%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 40%
• Ezetimibe 40%
• Prevalence 20%
• Prematurity 20%
• Apolipoprotein B 20%
• Low Density Lipoprotein Receptor 20%
• Ethanol 20%
• Combination Therapy 20%
• High Density Lipoprotein Cholesterol 20%
• Triacylglycerol 20%
• Acute Coronary Syndrome 20%
• Brain Ischemia 20%
• Peripheral Occlusive Artery Disease 20%
• Omega-3 Fatty Acid 20%
• Fibric Acid Derivative 20%
• Nicotinic Acid 20%
• Mipomersen 20%
• Nicotinic Acid Derivative 20%
• Lomitapide 20%
• Xanthoma 20%

Medicine and Dentistry

• Statin 100%
• Low Density Lipoprotein Cholesterol 83%
• Familial Hypercholesterolemia 66%
• Chronic Kidney Disease 66%
• Hyperlipidemia 66%
• Coronary Artery Disease 66%
• Proprotein Convertase 9 50%
• Hypolipidemic Agent 50%
• Diabetes Mellitus 33%
• Ezetimibe 33%
• Health Care 16%
• Arteriosclerosis Obliterans 16%
• Prevalence 16%
• Prematurity 16%
• LDL Receptor 16%
• Apolipoprotein B 16%
• High Density Lipoprotein Cholesterol 16%
• Glomerular Filtration Rate 16%
• Triacylglycerol 16%
• Combination Therapy 16%
• Brain Ischemia 16%
• Family History 16%
• Patient with Diabetes 16%
• Alcohol Consumption 16%
• Adjuvant Therapy 16%
• Clinical Guideline 16%
• Omega-3 Fatty Acid 16%
• Lifestyle Modification 16%
• Dietary Habit 16%
• Mipomersen 16%
• Niacin 16%
• Lomitapide 16%
• Cholesterol Absorption Inhibitor 16%
• Nicotinic Acid Derivative 16%
• Xanthoma 16%
• Acute Coronary Syndrome 16%